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e thank Drs. Schwerzmann and Meier for their interesting
omments on our study (1). However, we disagree with their
uggestion of possibly biased results.
In autopsy studies, patent foramen ovale (PFO) prevalence
anged from 15% (2) to 29% (3). Previous data showed that PFOs
ot detected by high-quality transthoracic echocardiography are
maller and associated with small right-to-left shunts (4); there-
ore, they are far less likely to be associated with embolic stroke
eatures (5). Moreover, our stroke risk estimates were almost
dentical to those from the SPARC (Stroke Prevention: Assess-
ent of Risk in a Community) study (6), which used transesoph-
geal echocardiography and reported a PFO prevalence of 24.3%.
herefore, although underdetection of smaller PFOs may have
ccurred in our study, the hazard ratio (HR) for PFO and ischemic
troke is very unlikely to have been artifactually low because of it.
It was shown that PFO has been associated with stroke not only
n the young but also in the elderly (7). In our study, 195 subjects
ere between the ages of 40 and 59; PFO prevalence in them was
7.4%, and the HR for ischemic stroke did not reach independent
tatistical significance after adjustment for other stroke risk factors.
e mentioned that our results do not exclude the possibility that
igher-risk subjects with PFO may exist because of associated
ofactors. Younger age could be one of these cofactors, or be more
requently associated with them. However, an independent stroke
isk from a PFO in the younger group was not apparent in our
tudy over a follow-up of approximately seven years. As for any
tudy, our results only apply within the context of the study
opulation examined and the duration of follow-up considered.
Among the risk factors included in the same multivariate model
ith PFO, not reported because of space limitations, increasing
ge (HR 1.06, 95% confidence interval [CI] 1.03 to 1.09 per year),
rterial hypertension (HR 1.89, 95% CI 1.02 to 3.50), and diabetes
ellitus (HR 2.93, 95% CI 1.79 to 4.81) were independentlyssociated with ischemic stroke, whereas hypercholesterolemiaHR 0.91, 95% CI 0.56 to 1.49), cigarette smoking (HR 1.06, 95%
I 0.65 to 1.75), and atrial fibrillation (HR 1.90, 95% CI 0.46 to
.88) were not. With the exception of atrial fibrillation, present in
nly 2.6% of the study cohort, risk factors appeared to affect the
troke risk in expected fashion. Therefore, there is no reason to
elieve that this may have been a source of bias in our results.
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